STAT+: Nestle Health Science will split profits from Seres microbiome drug, if it’s approved
Seres Therapeutics has announced a new deal with its long-time partner, Nestle Health Science, to bring Seres’ lead experimental microbiome drug to the U.S. market. That drug, SER-109, has been tested to treat the potentially lethal bacteria C. difficile.
The deal, announced Thursday, is worth $175 million upfront, with more than $300 million more in milestone payments. Each company will split the profits from the drug sales down the middle.
